Accelerate to discover

Back to filter

Related topics

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 23, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers

Agilent technologies

Nov 8, 2021

This technical overview describes advancements in detector technology, and highlights examples where optimal signal...

Jan 18, 2022

X-ray-virus-inactivation

Precision X-Ray

Oct 20, 2021

Ionizing radiation approaches are effective but use of radioactive radioisotopic elements have become difficult to...

Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Precision X-Ray

Oct 18, 2021

Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where...

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Jan 18, 2022

Falling in love with Magnetic resonance

Bruker Biospin

Oct 4, 2021

Magnetic Resonance (MR) is more than just analytical science, it is unique, it is a passion that won’t let you go

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey